Balanced Partnering Approach

We are leaders in the development of novel genomic therapies and have developed unique platform capabilities in gene therapy, genome editing, cell therapy and gene regulation.

With technology that has the potential to edit or regulate virtually any gene in the genome, we believe maximizing shareholder value must include a balanced approach between proprietary and externalized research. Our strategy is to develop our proprietary pipeline of product candidates in our therapeutic areas of focus, including inherited metabolic diseases, CNS diseases and immunology. We collaborate to harness the capabilities and competitive advantages of industry partners for product candidates that require expertise or resources outside our areas of focus. 


Interested in Partnering with Us?

Click here to contact Melita Sun Jung, Vice President, Head of Business Development.

Therapeutic Collaborations

Our business strategy is to do what we do best — develop gene therapy, genome editing, cell therapy and gene regulation products through research, preclinical and early stage clinical testing. We then partner when doing so will help us fully realize the value of certain programs through late stage development and commercialization.

Kite, a Gilead Company

Kite, a Gilead Company, and Sangamo are developing next-generation ex vivo cell therapies to treat cancer by using Sangamo’s zinc finger nuclease (ZFN) technology.

Pfizer Inc.

Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia. 

Sangamo and Pfizer are also collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.


Sanofi and Sangamo are developing gene-edited cell therapies for the treatment of beta thalassemia and sickle cell disease, using Sangamo’s zinc finger nuclease technology.

Shire International GmbH

Shire plc and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF gene regulation platform.

Non-Therapeutic Collaborations

ZFPs have applications beyond human therapeutics, from agriculture to generating cell lines for drug testing or manufacturing. 


The global scientific reagent company MilliporeSigma has licensed the exclusive right to use Sangamo's ZFP technologies to develop and market high-value laboratory research reagents, genome-engineered transgenic animals, and genome-engineered cell lines for commercial production of protein pharmaceuticals. MilliporeSigma markets ZFN-mediated genome editing products under the trademark CompoZr®, and is selling ZFN-engineered transgenic animals through SAGE™ Labs.

Dow AgroSciences LLC

Dow AgoSciences, a wholly-owned subsidiary of Dow Chemical Corporation, has licensed the exclusive right to use ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Dow AgroSciences markets ZFN-mediated genome edited plant products under the trademark EXZACT™ Precision Technology. We have retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFN products into human or animals for diagnostic, therapeutic, or prophylactic purposes.